secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001104659-24-027293
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics enters $750K manufacturing deal with director-owned CDMO Cell Ready
--------------------------------------------------------------------------------

- 3-year Master Services Agreement with Cell Ready LLC, owned by director/shareholder John Wilson.
- Work Order #1 for GMP drug product for MT-401 and/or MT-601; projected sum ≤$750K for Q1 2024.
- Agreement includes customary reps, warranties, and indemnification; either party may terminate for breach or insolvency.
- Additional work orders expected for the remainder of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924027293/0001104659-24-027293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924027293/tm247177d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-027293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer